Phase Ib (High Dose), Single Centre, Dose-escalating, Placebo-controlled, Randomized Study of a Live Attenuated B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2017
At a glance
- Drugs BPZE 1 (Primary)
- Indications Pertussis
- Focus Adverse reactions
- 05 Jul 2017 Results published in a ILiAD Biotechnologies media release.
- 06 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.